PetMed Express (PETS - Free Report) is a Zacks Rank #1 (Strong Buy) and has a growth style score of A - all of that puts the stock in my radar screen. Thing is, I have been watching this stock since the summer time when a short attack hit the stock and caused some wild swings.
Previous Video
Back on September 7, I filmed this video which focuses on Aggressive Growth stocks. You can access the video on this page (https://www.zacks.com/stock/news/275015/petmed-express-and-crox-are-aggressive-growth-rank-buys) and also hear about CROX as well.
Description
PetMed Express is a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats to retail customers. PetMed Express was founded in 1996 and is headquartered in Delray Beach, Florida.
Estimates
The stock is a Zacks Rank #1 (Strong Buy) because earnings estimates have moved higher. The Zacks Consensus Estimate for 2017 has moved from $1.42 to $1.68 over the last sixty days.
The Zacks Consensus Estimate for 2018 also increased over the same time period. The number moved from $1.51 to $1.80.
Short Interest
There is a huge short interest in this stock. That means that investors believe that the stock will move lower and they have borrowed shares, sold them and hope to buy them back lower. Thing is, the short is not working. The site ShortSqueeze.com shows that the float is 30% short... and that is a huge amount of shorts.
As fundamentals continue to improve, the shorts are more likely to cover their bets and take a loss. This is could be a classic short squeeze.
Chart
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
PetMed Express (PETS - Free Report) is a Zacks Rank #1 (Strong Buy) and has a growth style score of A - all of that puts the stock in my radar screen. Thing is, I have been watching this stock since the summer time when a short attack hit the stock and caused some wild swings.
Previous Video
Back on September 7, I filmed this video which focuses on Aggressive Growth stocks. You can access the video on this page (https://www.zacks.com/stock/news/275015/petmed-express-and-crox-are-aggressive-growth-rank-buys) and also hear about CROX as well.
Description
PetMed Express is a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats to retail customers. PetMed Express was founded in 1996 and is headquartered in Delray Beach, Florida.
Estimates
The stock is a Zacks Rank #1 (Strong Buy) because earnings estimates have moved higher. The Zacks Consensus Estimate for 2017 has moved from $1.42 to $1.68 over the last sixty days.
The Zacks Consensus Estimate for 2018 also increased over the same time period. The number moved from $1.51 to $1.80.
Short Interest
There is a huge short interest in this stock. That means that investors believe that the stock will move lower and they have borrowed shares, sold them and hope to buy them back lower. Thing is, the short is not working. The site ShortSqueeze.com shows that the float is 30% short... and that is a huge amount of shorts.
As fundamentals continue to improve, the shorts are more likely to cover their bets and take a loss. This is could be a classic short squeeze.
Chart
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on PETS - FREE
Get the latest research report on CROX - FREE